期刊文献+

甲基强的松龙联合β-干扰素治疗多发性硬化疗效观察 被引量:4

下载PDF
导出
摘要 目的:观察甲基强的松龙联合β-干扰素治疗多发性硬化的临床疗效。方法:选取郑州大学第一附属医院收治的72例多发性硬化患者,随机分为观察组和对照组,各36例。所有患者均采用甲基强的松龙治疗,在此基础上观察组同时给予β-干扰素皮下注射,20 mg/次,3次/周,疗程为3个月。观察并比较两组患者治疗效果及不良反应发生情况。结果:观察组治疗总有效率为91.6%,对照组总有效率为75.1%,差异具有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:甲基强的松龙联合β-干扰素治疗多发性硬化效果显著,可促进神经功能恢复,降低残障程度,安全性高,值得在临床中推广应用。
出处 《河南医学研究》 CAS 2014年第12期55-56,共2页 Henan Medical Research
  • 相关文献

参考文献7

  • 1Moghaddasi M,Aghaei M.Assessment of bone densitometry in Iranian patients with multiple sclerosis:A case-control study[J].Iran J Neurol,2013,12(1):9-14.
  • 2刘喷飓,张星虎,周衡,刘云,刘君,李莉莉,沈彦.干扰素-β-1b治疗多发性硬化的疗效及不良反应观察[J].中国神经免疫学和神经病学杂志,2011,18(1):37-40. 被引量:8
  • 3Boeru G,Milanov I,De Robertis F,et al.Extavi Ject 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis:a prospective European study[J].Med Devices(Auckl),2013,(6):175-184.
  • 4周文斌,崔玉真,肖波.多发性硬化的流行病学研究(综述)[J].中国神经免疫学和神经病学杂志,2005,12(6):373-375. 被引量:25
  • 5Freedman M S.Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-βtherapy[J].Eur J Neurol,2013,10(15):158-160.
  • 6Brunetti L,Wagner M L,Maroney M,et al.Teriflunomide for the treatment of relapsing multiple sclerosis:a review of clinical data[J].Ann Pharmacother,2013,47(9):1153-1160.
  • 7王子峰.IFNβ-1b治疗复发—缓解型多发性硬化疗效观察[J].山东医药,2011,51(14):105-106. 被引量:6

二级参考文献31

  • 1胡学强,黎锦如,潘勇辉,黄秋云,雷振宏,刘天琪.广东省容奇镇多发性硬化患病率调查[J].中山医科大学学报,1997,18(1):79-80. 被引量:7
  • 2Goodin DS, Frohman EM,Garmany GP, et al. Disease modifying therapies in multiple sclerosis. Report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS council for Clinical Practice Guidelines[J]. Neurology, 2002, (58) : 169-178.
  • 3McDonald WI,Compston A,Edan G, et al. Recommended diagnostic criteria for multiple selerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis[J]. Ann Neurol, 2001, (50): 121-127.
  • 4Kurtzke JF. Rating neurological impairment in multiple sclerosis:an expanded disability status scale(EDSS)[J]. Neurology, 1983, (33): 1444-1452.
  • 5The IFN-β Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial[J]. Neurology, 1995,45 (7) : 1277- 1285.
  • 6PRISMS(Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis)Study Group. Randomized double blind placebo-controlled study of interferon beta-la in relapsing/ remitting multiple sclerosis[J]. Lanrot. 1 QQR. 552.
  • 7Suhayl Dhib-Jalbut. Mechanisms of action of interferons and glatirameracetate in multiple sclerosis[J]. Neurology, 2002,58 (8 Suppl 4):3-9.
  • 8Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis[J]. Arch Neurol, 2005,62 (5) : 785-792.
  • 9PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS [J]. Neurology, 2001,56(12) : 1628-1636.
  • 10Newilley LK,Goodin DS,Goodkin DE, et al. Side effect profile of interferon beta 1b in MS: results of an open label trial [J]. Neurology,1996,46(2) : 552-554.

共引文献35

同被引文献39

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部